GSK's New Vaccine Hire Looks Beyond Covid in Quest for Next Hit

GSK Plc is planning to launch a Covid shot that comes almost two years after Pfizer Inc. took the world by storm. For Phil Dormitzer, it’s a reminder of why he was hired at the UK drugmaker: to help return its immunization business to the top after it stumbled during the pandemic. Dormitzer, who left Pfizer to become GSK’s global vaccine research chief, will need to move beyond the Covid shot and deliver some breakthroughs to challenge his former employer and other rivals. The pressure is on as the British company prepares to spin off its consumer unit this month. “The focus on vaccines is huge right now,” Dormitzer said in an interview from outside Boston, where he’s based. “After the separation of the consumer-health business, it will be an even more prominent part of the overall organization.”